Clinical Trials Logo

Spinocerebellar Ataxia Type 2 clinical trials

View clinical trials related to Spinocerebellar Ataxia Type 2.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05826171 Active, not recruiting - Clinical trials for Spinocerebellar Ataxia Type 3

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia

PRIME-Ataxia
Start date: February 6, 2023
Phase: N/A
Study type: Interventional

PRIME-Ataxia is a randomized controlled trial that aims to determine the feasibility and efficacy of an 8-week telehealth intervention of high intensity aerobic exercise prior to balance training compared to an 8-week telehealth intervention of low intensity exercise prior to balance training in people with spinocerebellar ataxias (SCAs). The investigators additionally aim to explore changes in motor skill learning on a novel motor skill task in a sub-group of participants pre and post intervention.

NCT ID: NCT04268147 Active, not recruiting - Friedreich Ataxia Clinical Trials

Instrumented Data Exchange for Ataxia Study

IDEA
Start date: June 1, 2019
Phase:
Study type: Observational

This research study is testing body-worn sensors to measure movement during simple tests of coordination, in order to evaluate the progression and severity of ataxia.

NCT ID: NCT03701399 Active, not recruiting - Clinical trials for Spinocerebellar Ataxias

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

NCT ID: NCT03408080 Active, not recruiting - Clinical trials for Spinocerebellar Ataxias

Open Pilot Trial of BHV-4157

Start date: December 15, 2017
Phase: Phase 3
Study type: Interventional

24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia. BHV-4157 is a pro-drug of riluzole (which is currently FDA-approved for ALS, Lou Gehrig's disease). There will be 5 visits to UCLA required--Screening when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; Baseline when general and neurological examination and questionnaires will be administered and study drug dispensed; Week 4 and Week 12 when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; 2 weeks after finishing study drug when general examination and blood testing will be completed. There is an option for a 36 week extension of the study drug trial.